Search clinical trials for: Ertugliflozin 5 mg

Total 18024 results

Merck Sharp & Dohme LLC
Pfizer

Completed

Study of Safety and Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes And Hypertension (MK-8835-042)

Hypertension | Diabetes Mellitus, Type 2
Merck Sharp & Dohme LLC
Pfizer

Active, not recruiting

Ertugliflozin Type 2 Diabetes Mellitus (T2DM) Pediatric Study (MK-8835/PF-04971729) (MK-8835-059)

Type 2 Diabetes Mellitus

United States, Belgium, Canada, Colombia, Costa Rica, Dominican Republic, France, Guatemala, Hungary, Israel, Italy, Malaysia, Mauritius, Mexico, Philippines, Poland, Russian Federation, Saudi Arabia, Turkey, Ukraine, United Arab... and more
Merck Sharp & Dohme LLC
Pfizer

Completed

A Study of the Efficacy and Safety of Ertugliflozin in Participants With Type 2 Diabetes Mellitus With Stage 3 Chronic Kidney Disease Who Have Inadequate Glycemic Control on Antihyperglycemic Therapy (MK-8835-001)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC
Pfizer

Completed

Effects of Once and Twice Daily Dosing Regimen of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-040)

Diabetes Mellitus, Type 2 | Adult
Merck Sharp & Dohme LLC
Pfizer

Completed

A Study to Evaluate the Efficacy and Safety of Ertugliflozin in Asian Participants With Type 2 Diabetes and Inadequate Glycemic Control on Metformin Monotherapy (MK-8835-012)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC
Pfizer

Completed

Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006; VERTIS SITA2)

Type 2 Diabetes Mellitus
Getz Pharma

Recruiting

Effect of Erugliflozin On Liver Fat, Liver Fibrosis and Glycemic Control in Type II DM Patients With NASH/NAFLD (Ertu-NASH)

Body Weight Changes | Liver Fat | Tolerance | Liver Fibrosis | Glycemic Control | Waist Circumference

Pakistan
University Hospitals Cleveland Medical Center

Terminated

Evaluating Metabolic Mechanisms of Ertugliflozin in Diabetes & Heart Failure (EMMED-HF)

Diabetes Mellitus, Type 2 | Heart Failure, Diastolic

United States
Medical University of Graz
Medical University of Vienna; Landesklinkum Wiener Neustadt; Klinik Ottakring; Medical... and other collaborators

Terminated

Ertugliflozin to Reduce Arrhythmic Burden in ICD/CRT patientS (ERASe-Trial) - a Phase III Study (ERASE)

Implantable Cardioverter-Defibrillators | Heart Failure With Reduced Ejection Fraction | Cardiac Resynchronization Therapy | Heart Failure With Mid Range Ejection Fraction

Austria
Merck Sharp & Dohme LLC
Pfizer

Completed

Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC
Pfizer

Completed

Study Of Safety And Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-016)

Diabetes Mellitus, Type 2
Merck Sharp & Dohme LLC
Pfizer

Completed

Study To Estimate The Relative Bioavailability of Ertugliflozin (PF-04971729, MK-8835) in Healthy Adult Participants (MK-8835-039)

Healthy
Merck Sharp & Dohme LLC
Pfizer

Completed

A Study of the Efficacy and Safety of Ertugliflozin Monotherapy in the Treatment of Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Despite Diet and Exercise (MK-8835-003, VERTIS MONO)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC
Pfizer

Completed

Ertugliflozin vs. Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC
Pfizer

Completed

Pharmacokinetics, Safety, and Tolerability of Ertugliflozin (MK-8835/PF-04971729) in Participants With Hepatic Impairment and in Healthy Participants (MK-8835-014)

Type 2 Diabetes Mellitus | Hepatic Impairment
Merck Sharp & Dohme LLC
Pfizer

Completed

A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007).

Type 2 Diabetes Mellitus
Amsterdam UMC, location VUmc

Completed

Renal Oxygenation, Oxygen Consumption and Hemodynamic Kinetics in Type 2 DIabetes: an Ertugliflozin Study. (ROCKIES)

Type 2 Diabetes Mellitus | Diabetic Nephropathy | Diabetic Kidney Disease | Renal Hypoxia | Renoprotection | SGLT2 Inhibitor | Ertugliflozin

Netherlands
Merck Sharp & Dohme LLC
Pfizer

Completed

A Phase 1 Study of Ertugliflozin in Healthy Male Participants (MK-8835-020)

Type 2 Diabetes Mellitus
Pfizer

Completed

Multiple Oral Doses Of PH-797804 In Healthy Japanese Adult Subjects

Healthy

United States
Anesiva, Inc.

Completed

Safety and Efficacy Study of 4975 in Patients Undergoing Total Knee Replacement

Total Knee Arthroplasty (Replacement)

United States
University Health Network, Toronto
Merck Sharp & Dohme LLC; University Medical Center Groningen; University of Toronto and other collaborators

Completed

ERtugliflozin triAl in DIabetes With Preserved or Reduced ejeCtion FrAcTion mEchanistic Evaluation in Heart Failure (ERADICATE-HF)

Heart Failure | Type 2 Diabetes Mellitus

Netherlands, Canada
GlaxoSmithKline

Terminated

Assessment of the Pharmacokinetics of GSK1278863 and Metabolites in Normal Subjects and Subjects With Renal Impairment

Anaemia

United States
Shandong Suncadia Medicine Co., Ltd.

Not yet recruiting

A Study to Assess the Bioequivalence of Fixed Dose Combination of HR20033 Relative to Co-administration of the Individual Components in Healthy Chinese Subjects

Type II Diabetes
Suzhou Kintor Pharmaceutical Inc,

Completed

Phase II Study Evaluating the Efficacy and Safety of KX-826

Androgenetic Alopecia (AGA)

China
Janssen Research & Development, LLC

Terminated

An Efficacy and Safety Study of Atabecestat in Participants Who Are Asymptomatic at Risk for Developing Alzheimer's Dementia (EARLY)

Asymptomatic Amyloid-positive

United States, United Kingdom, Belgium, Germany, Spain, Japan, Australia, Netherlands, Canada, Denmark, Mexico, Finland, Sweden
Proteimax Biotechnology Israel LTD

Completed

Effect of Consumption of Pep19 on Quality of Life

Quality of Life | Obesity | Sleep Quality

United States
Laboratorios Andromaco S.A.

Completed

Bioavailability of Clotiazepam 5 mg With Regards to Reference Product

Bioequivalence

Chile
Edgewise Therapeutics, Inc.
Medpace, Inc.; SYSNAV; ImagingNMD

Active, not recruiting

Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)

Becker Muscular Dystrophy

United States, Spain, Belgium, Denmark, Netherlands, Israel, United Kingdom, New Zealand, France, Italy, Australia, Germany
GSNOR Therapeutics, Inc.

Unknown

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Cavosonstat Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)
Gannex Pharma Co., Ltd.

Completed

Study to Evaluate the Safety and Efficacy of ASC42 Tablets in Subjects With Primary Biliary Cholangitis

Primary Biliary Cholangitis

China
Daiichi Sankyo, Inc.

Completed

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of ASB17061 Capsules in Adult Subjects With Atopic Dermatitis

Atopic Dermatitis

United States
AstraZeneca

Completed

Study to Investigate the Pharmacodynamic Effect of a Single Dose of AZD2516 in Healthy Male Subjects

Reflux

Netherlands, Belgium
Estetra

Completed

Safety, Tolerability and Pharmacokinetics of Estetrol (E4) After Single and Multiple Oral Doses in Healthy Female Volunteers

Menopause | Contraception

Bulgaria
Bayer
Merck Sharp & Dohme LLC

Completed

A Study to Learn How Safe Starting Vericiguat at a Dose of 5 Milligrams is in Participants With Chronic Heart Failure With Reduced Ejection Fraction

Chronic Heart Failure With Reduced Ejection Fraction

Spain, Italy, United States, Poland, Hungary, Sweden, Argentina
Cytokinetics

Enrolling by invitation

Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM (FOREST-HCM)

Symptomatic Hypertrophic Cardiomyopathy (HCM)

United States, France, Israel, Spain, Germany, United Kingdom, Canada, Italy, Portugal, Poland, Hungary, Denmark, Netherlands, Czechia
Taisho Pharmaceutical Co., Ltd.

Completed

A Pharmacokinetic Study of TS-142 in Patients with Hepatic Impairment

Patients with Mild or Moderate Hepatic Impairment

Japan
Taisho Pharmaceutical Co., Ltd.

Completed

Long-Term Study of TS-142 in Patients with Insomnia

Patients with Insomnia

Japan
Ferring Pharmaceuticals

Terminated

26 Week Efficacy and Safety Trial for Patients With Chronic Idiopathic Constipation

Chronic Idiopathic Constipation

Israel, Belgium, United States, United Kingdom, Germany, Poland, Brazil, Canada, Czech Republic, South Africa
PHARMENTERPRISES LLC

Completed

Study to Assess Safety, Tolerability and Pharmacokinetics of Treamid in Healthy Volunteers

Metabolic Syndrome
Aga Khan University

Completed

Effectiveness of Nigella Sativa (Kalonji) Seed in Dyslipidemia

Hypertension | Diabetes Mellitus | Hypercholesterolemia | Metabolic Syndrome X

Pakistan
Suzhou Kintor Pharmaceutical Inc,
Suzhou Koshine Biomedica, Inc.

Active, not recruiting

Phase III Study of KX-826 With Adult Male Patients With AGA

Androgenetic Alopecia

China
Boryung Pharmaceutical Co., Ltd

Withdrawn

A Study to Compare the Pharmacokinetics and Safety/Tolerability of BR-UPS (Ulipristal Acetate) 5 mg Tablet With Inisia (Ulipristal Acetate) 5 mg Tablet

Uterine Myoma

Korea, Republic of
University of Pennsylvania
National Heart, Lung, and Blood Institute (NHLBI); National Institute of Arthritis... and other collaborators

Completed

The Assessment of Prednisone In Remission Trial - Centers of Excellence Approach (TAPIR)

Granulomatosis With Polyangiitis

United States, Canada
Bayer

Completed

Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED)

Heart Failure

Belgium, France, Spain, Greece, Portugal, Japan, United States, Singapore, Austria, Germany, Korea, Republic of, Poland, Australia, Israel, Netherlands, Switzerland, Taiwan, Bulgaria, Canada, Czechia, Denmark, Hungary, Italy, Sweden, United...
Pfizer

Terminated

An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia

Schizophrenia

United States
Kyowa Kirin Co., Ltd.

Completed

A Study of OPC-262 in Patients With Type 2 Diabetes

Diabetes Type 2

Japan
Actinogen Medical
Avance Clinical Pty Ltd.

Completed

A Double-Blind, Placebo-Controlled, Dose Ranging Study of Xanamem® in Healthy Elderly Volunteers (XanaMIA-DR)

Mild Cognitive Impairment | Alzheimer's Disease

Australia
Bayer

Completed

Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure With Reduced Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-REDUCED)

Heart Failure

Belgium, France, Switzerland, United States, Spain, Greece, Japan, Singapore, Austria, Germany, Korea, Republic of, Poland, Denmark, Israel, Netherlands, Taiwan, Bulgaria, Canada, Sweden, Czechia, Australia, Italy, Hungary, United Kingdom
Conatus Pharmaceuticals Inc.

Completed

Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis (ENCORE-NF)

Liver Diseases | Fibrosis | Non-alcoholic Steatohepatitis

United States, Spain, Germany
Takeda

Completed

A Study of TAK-861 in Participants With Narcolepsy Type 2

Narcolepsy Type 2

Spain, United States, Japan, Italy, France, Germany, Australia, Netherlands, Finland, Norway, Sweden, Switzerland

Search clinical trials for: Ertugliflozin 5 mg

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zimbabwe

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations